• Profile
Close

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

Vaccine Oct 19, 2017

Sirima SB, et al. - Safety and immunogenicity of Plasmodium falciparum Apical Membrane Antigen 1 Diversity Covering (PfAMA1-DiCo) candidate vaccine was tested among European and African adults who received AMA1-DiCo with either Alhydrogel or GLA-SE. Findings revealed that regardless of the adjuvant, AMA1-DiCo vaccine was safe and immunogenic, however, GLA-SE appeared more potent than Alhydrogel at inducing IgG responses.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay